InVentiv grabs Catalina Health with eye on patient adherence

Outsourcing magnate inVentiv Health ($VTIV) is padding its patient-adherence offerings, snapping up Catalina Health and merging the company with its Adheris subsidiary, a move it said creates the nation's largest provider of such services.

Without disclosing financial terms, inVentiv said the deal expands its medication-adherence client base to about 30,000 pharmacies across the country, representing 65% of all retail prescriptions. Adheris sends personalized messages to patients based on the recommendations of their clinicians, reminding them of when to take medications and when to refill prescriptions.

InVentiv had already developed a system of predictive analytics to boost the efficacy of its patient messaging, and now adding Catalina Health's capacity and nationwide reach gives it an unrivaled offering, inVentiv Health Patient Outcomes President Mark Dmytruk said.

"Over the past year, we've seen growing client demand for coordinated patient messaging and an increased focus on patient-centric outcome strategies," Dmytruk said in a statement. "The acquisition improves our ability to deliver exactly what our clients need."

Catalina Health, a former division of Catalina, will operate from here on out under the Adheris name, and former company president Renee Selman will preside over the combined business.

The deal is part of a busy year for inVentiv as it looks to expand its all-of-the-above approach to pharma services. Last month, the Massachusetts company expanded its eClinical presence by launching an online network of physicians for trials, building off a separate agreement with PatientsLikeMe that allows that site's more than 200,000 members to view and apply for relevant studies from inVentiv's clients. Meanwhile, the CRO is deepening its consulting services, in September introducing Breakaway Policy Strategies, a joint venture offering policy advice to drugmakers.

- read the announcement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

Genae's CEO says the transaction reflects recent focus on digital health and data-driven services.